A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）
Status:
Not yet recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with
relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of
therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.